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ABSTRACT
The Effect of Melatonin or Maternal Nutrient Restriction on Cell Proliferation in the
Ovine Placenta
Adam W. Eifert
Our objectives were to assess melatonin receptor dependent modulation of placental cell
proliferation following treatment with either melatonin, luzindole (melatonin receptor 1 and 2
antagonist), or vehicle. In addition, a second study was conducted to assess placental cell
proliferation following dietary melatonin treatment in a maternal nutrient restriction model. For
the first experiment, 14 primiparous ewes were fitted with Alzet mini osmotic pumps attached to
a catheter and infused with vehicle, melatonin, or luzindole from d 62 to 90 of gestation. Ewes
were euthanized and placentomes collected for analysis at the end of the 4 week infusion. For the
second experiment, 31 primiparous ewes were supplemented with 5 mg of melatonin per d
(MEL) or no melatonin (CON) and allocated to receive 100% (adequate) or 60% (restricted) of
their nutrient requirements from d 50 to 130 of gestation. On d 130 of gestation, ewes were
euthanized and placentomes were collected for analysis. Placentomes from both experiment 1
and 2 were examined for percentage of proliferating cells using an immunofluorescence assay. A
Ki-67 mouse monoclonal antibody was used to stain proliferating cells within each tissue section
and was compared to non-proliferating cells stained with DAPI to determine the percentage of
proliferating cells within each sample. Total RNA, DNA and protein was also analyzed within
each sample. For experiment 1, cell proliferation in the cotyledon and caruncle was not affected
(P > 0.30) by vehicle, melatonin or luzindole infusions. Dietary melatonin supplementation from
mid to late gestation may impact cotyledon cell proliferation; however chronic infusion of
melatonin or luzindole did not change proliferation in either the cotyledon or caruncle. Treatment
did not alter the concentrations of RNA, DNA, protein (P ≥ 0.15), or the ratio of RNA:DNA and
the ratio of protein:DNA (P ≥ 0.17). For experiment 2, there was no melatonin supplementation
by nutritional plane interactions (P > 0.50) on cellular proliferation in either the cotyledon or
caruncle. There was a tendency (P = 0.08) for melatonin supplemented ewes to have an
increased percentage of proliferating cells in the cotyledon; however, this effect of melatonin
was absent (P > 0.30) in the caruncle. Nutritional plane did not alter cellular proliferation in
either the cotyledon (P > 0.70) or caruncle (P > 0.50). There was no effect of nutritional plane or
melatonin treatment on the concentration of DNA or protein (P ≥ 0.21) in caruncular tissue.
However there was an interaction on RNA (P = 0.02) in caruncular tissue which may be due to
an increase in gene expression following melatonin treatment. There was no effect of treatment
or nutritional plane on DNA, RNA, protein (P ≥ 0.20) as well as no effect on RNA:DNA or
protein:DNA (P ≥ 0.25). In summary, melatonin may alter placental growth in ewes with IUGR;
however, this needs further investigation.
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STATEMENT OF THE PROBLEM
During the neonatal period, offspring with low birth weight have a higher incidence of
morbidity and mortality, while surviving offspring with low birth weight have lower rates of
gross energy accretion and poor growth rates (Barker and Clark 1997; Greenwood et al. 1998).
When birth weights are below average, lamb mortality rates can be as high as 20 to 50%, which
can be detrimental to the producer (Mukasa-Mugerwa et al. 1994). Lamb survivability can be
associated with several factors and, when birth weights are low, total lamb loss rate can be as
high as 5%. As of 2013, the total sheep and lamb inventory in the United States is estimated to
be approximately 5.34 million with an annual loss of 267,000 lambs due to low birth weight
(NASS, 2013). Assuming 30 to 40 pounds of meat harvested per lamb, we could estimate an
annual loss of over 10 million pounds of meat due to low birth weight which amounts to millions
of dollars in lost revenue. If the amount of offspring with low birth weight could be reduced, we
could increase production, revenue and amount of meat available for consumption, which is not
only important for farmers in the U.S., but also important for developing countries that rely on
sheep as a source of protein.
Melatonin is produced in the pineal gland located near the hypothalamus in the brain and
is involved in regulating several physiological processes including reproduction, sleep, energy
balance and behavior in a variety of species (Almeida et al. 2011). Melatonin is unique in that it
is one of the few hormones that is able to cross the placenta and be delivered to the fetus
unaltered (Torres-Farfan et al. 2008). Studies have shown that melatonin supplementation has
been associated with decreasing uterine contractility in the rat, stimulating the secretion of
progesterone (Forcada et al. 2006), increasing the release of gonadotropins from the pituitary in
the ewe (Aleandri et al. 2006), and removal of the pineal gland in pregnant rats has been linked
1

to an elevated incidence of spontaneous abortions (Sandyk et al. 1992).Currently, very little
research has been conducted on melatonin supplementation and its effects on increasing birth
weight and uteroplacental blood flow. If melatonin supplementation proves to be effective in
increasing both of these, it could be used to rescue compromised pregnancies and subsequently
reduce fetal mortality. Our objectives were to determine the effect of melatonin
supplementation, either through the diet or chronic infusion, on cellular proliferation in the
placentome as well as its effect on the concentration of RNA, DNA and protein in intra-uterine
growth restriction (IUGR) pregnancies.
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REVIEW OF LITERATURE

Melatonin Biosynthesis
Production of melatonin by the pineal gland, located near the hypothalamus in the brain,
has several important physiological roles including regulating sleep, reproduction, molting,
immune responses, energy balance, and behavior within a broad range of species (Almeida et al.
2011). Deficiencies in pineal secretion that cause a reduction in melatonin production can be
associated with insomnia, anxiety, elevated estrogen/progesterone ratio, and immune suppression
(Arendt 1998). The biosynthesis pathway for the production of melatonin was adapted from Voet
and Voet (2004). The first step in the biosynthesis of melatonin is hydroxylation of tryptophan
by tryptophan hydroxylase to 5-hydroxytryptophan which requires tetrahydrobiopterine as a
cofactor. Decarboxylation of 5-hydroxytryptophan by 5-hydroxytryptophan decarboxylase
produces serotonin. Serotonin, with the use of acetyl-coA, is converted to N-acetyl-serotonin by
serotonin acetyltransferase. The final step is the conversion of N-acetyl-serotonin to melatonin
by 5-hydroxyindole-O-methyltransferase (HIOMT), which is the rate limiting step in melatonin
synthesis. HIOMT is known as the “melatonin rhythm enzyme” since it plays a time keeping role
between environmental signals and the production and release of melatonin (Ganguly et al.
2002).
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Sensupta A, and Tosini G. 2011.
The NEI Connection, 2011.

Melatonin levels in ovine plasma are low during the photophase and usually begin to
increase at the start of the scotophase and peak between midnight and 3:00 hours followed by a
rapid decrease in concentration (Yellon and Longo 1987; Ganguly et al. 2002). However, the
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timing for the rise in melatonin concentration is dependent on the season (i.e. short days vs. long
days) when the start of the scotophase occurs. Plasma concentrations of melatonin have been
found to be highly variable among individuals of the same species and may be under strong
genetic control (Zarazaga et al. 1998). A study conducted by Zarazaga et al. (1998) examined the
average concentrations of melatonin in the blood plasma of sheep during both short (December)
and long (June) days. They found that during short days mean nocturnal plasma melatonin
concentrations were 400.4 pg/mL compared to long days having a mean concentration of 328.3
pg/mL although it was highly variable among individuals. A similar study conducted by Coon et
al. (1999) placed lambs in groups of either high or low genetic value based on endogenous
nocturnal plasma melatonin concentration of their parents. They found that mean nocturnal
plasma melatonin concentrations varied significantly among lambs with a high genetic value
(344.1 pg/mL) compared to lambs with a low genetic value (189.7 pg/mL). This study indicated
that nocturnal melatonin concentrations are under genetic control.

Metabolic Clearance of Melatonin
Upon synthesis, melatonin is immediately released into circulation and is found in
circulation within a very short period (Pandi-Perumal et al. 2006). Zarazaga et al. (1998) found
that melatonin to be ten-fold higher in the blood plasma compared with saliva and concentrations
in the third ventricle are 20-30 times higher than that found in the blood. A study done by
Calustrat et al. (2005) found the half life of melatonin to be bi-exponential with a first
distribution half-life of two minutes followed by the second of 20 minutes. Keveder and McIssac
(1961) found that the majority of melatonin (70%) is cleared by the kidneys while the remaining
30% is excreted in the feces.
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The catabolism of melatonin occurs primarily in the liver and is first hydroxylated in the
C6 position by cytochrome P450 mono-oxygenases specifically CYP1A1, CYP1A2, CYP1B1,
and CYP2C19 (Ma et al. 2005; Pandi-Perumal et al. 2006). After hydroxylation the product, 6hydroxymelatonin, is conjugated with sulfate and is excreted in the urine as 6sulfatoxymelatonin (aMT6S) (Claustrat et al. 2005). Melatonin can also be demethylated by
CYP1A2 to N-acetylserotonin, which is the precursor to melatonin in the synthesis pathway
(Pandi-Perumal et al. 2006). Ma et al. (2005) studied the metabolism of melatonin by human
cytochrome P450, and found that CYP1A2 and CYP2C19 were mainly responsible for the hepatic
clearance of melatonin from blood plasma. They also found that CYP1B1 was not expressed in
high levels within the liver but has a more wide spread distribution in extra-hepatic tissues
indicating its role in the 6-hydroxylation of melatonin outside the liver (Ma et al. 2005).
Secondary sites of melatonin metabolism vary depending on the tissue in which it is located.
Organs derived from neural tissues such as the pineal gland and the retina contain melatonindeacetylating enzymes (Pandi-Perumal et al. 2006). These enzymes can either be specific for
melatonin deacetylases or aryl acylamidases which are less specific (Hardeland et al. 1996).
Melatonin can be deacetylated to 5-methoxytryptamine in any tissue containing serine-sensitive
acetylcholinesterase due to its aryl acylamidase side activity (Hardeland et al. 1993; Hardeland et
al. 1996). Not only can melatonin be catabolized by specific enzymes, but it can also be broken
down non-enzymatically both intra and extra-cellularly by free radicals and antioxidants (PandiPerumal et al. 2006). The non-enzymatic metabolism of melatonin is achieved by hydroxylation
using two hydroxyl radicals, which converts melatonin into 3-hydroxymelatonin and is removed
from the body through the urine (Tan et al. 1998). In the brain a large portion of melatonin is
metabolized to kynuramine derivatives specifically N1-acetyl-N2-formyl-5-methyoxykynuramine
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(AMFK) (Hirata et al. 1974; Pandi-Perumal et al. 2006). Arylamine formidase or
hemoperoxidases then deformylates AMFK to N1-acetyl-5-methoxykynuramine (AMK) and
recent studies have found that this reaction contributes to about 1/3 of the total catabolism of
melatonin (Hardeland et al. 2006). Silva et al. (2004) found that the metabolism of melatonin to
AMFK played an important role in the innate immune response by inhibiting the release of proinflammatory cytokines, specifically interlukin-8 (IL-8), and tumor necrosis factor-alpha (TNFα) from neutrophils which are known to cause inflammation.

Regulation of Melatonin
The regulation of melatonin involves several mechanisms that are in turn regulated by the
exposure to light (Karsh et al. 1991; Arendt 1995). The suprachiasmatic nucleus (SCN) is the
bodies’ circadian oscillator and is part of the photoneuroendocrine system. The circadian rhythm
is controlled by the circadian oscillator that generates a rhythm which repeats roughly every 24
hours (Moore and Klein 1974; Klein and Moore 1979; Reppert et al. 1981). There are two main
systems that control the signals sent to the SCN. The first appears to be classic rods and cones
located within the retina of the eye (Bronstein et al. 1987; Nelson and Takahashi 1991). The
second system is comprised of melanopsin-positive retinal ganglion (MPRG) cells (Ganguly et
al. 2002). These specialized cells are a specific type of photoreceptors located in the ganglion
cell layer of the retina (Ganguly et al. 2002). Information on day light, perceived from the rods
and cones, is delivered to the MPRG cells which directly innervate the SCN which either causes
an increase or decrease in aralkylamine-N-acetyltransferase (AANAT) activity depending on the
current light conditions leading to an increased production of melatonin when AANAT levels are
high (Ganguly et al. 2002). Light can either have a stimulatory or inhibitory effect on melatonin
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synthesis. The stimulatory effects of light increase AANAT activity and melatonin synthesis
while the inhibitory effects of light interrupt the transmission of signals sent from the SCN to the
pineal gland decreasing AANAT activity and melatonin synthesis (Klein and Weller 1972; Klein
1985; Ganguly et al. 2002).
The melatonin rhythm generating system involves a complex pathway where signals are
sent from the retina to locations within the brain. As light conditions are registered by the retina,
the MPRG cells in cooperation with rods and cones send signals to the SCN on the current
perceived lighting conditions (Ganguly et al. 2002). This information is then sent to the
paraventricular nucleus (PVN) which is innervated by cells from the SCN (Kalsbeek and Bujis
2002). Cells in the PVN innervate the “medial forebrain bundle and reticular formation to
preganglionic cells in the intermediolateral cell column of the spinal cord” (Ganguly et al 2002).
The signal is then sent to the superior cervical ganglia and transferred to the pineal gland by the
inferior carotid nerve and nervi conarii (Ganguly et al 2002). The pineal gland contains
norepinephrine (NE) containing fibers which are stimulated by the signals received from the
inferior carotid nerve and nervi conarii (Sugden et al. 1985; Vanecek et al. 1985). When
stimulated these NE containing fibers release NE that binds to α1 and β1 adrenergic receptors
(AR) of the pinealocyte (Sugden et al. 1985; Vanecek et al. 1985). The binding of NE to β1-AR
receptors results in the production of adenylate cyclase through the Gs pathway (Ganguly et al
2002). Norepinephrine binding to the α1-adernergic receptors increases intracellular calcium
levels as well as stimulating the production of diacylglycerol (DAG) activating protein kinase C
(PKC; Sugden and Klein 1988). Adenylate cyclase in cooperation with PKC increases the
production of the second messenger cyclic AMP (Sugden et al. 1985). Cyclic AMP, through
several intracellular mechanisms, increases the activity of AANAT within the pinealocyte
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(Ganguly et al. 2002; Yu et al. 1993). The increased activity of AANAT significantly enhances
the conversion of serotonin (5-hydroxytryptamine) to N-acetyl-serotonin which is then converted
to melatonin by hydroxyindole-o-methyltransferase (Ganguly et al. 2002). The newly
synthesized melatonin is immediately released into circulation, and the amount released is
controlled by the pineal gland (Illnerova et al 1978). As the nocturnal period ends, neural
stimulation begins to decrease leading to a reduction in cyclic AMP and subsequently a reduction
in the activity of HIOMT returning circulating melatonin levels back to a diurnal state (Ganguly
et al. 2002).
The amphibian melatonin receptor was first cloned in 1994 followed by the human and
sheep receptor soon after (Arendt 1995). The activity of melatonin receptors fluctuate throughout
the day depending on light conditions and is based upon the circulating levels of melatonin
(Witt-Enderby et al. 2003). Signal transduction cascades can either be activated or inhibited by
melatonin which acts either directly through its receptor or independently (Witt-Enderby et al
2003). Melatonin can act independently from its receptor due to its lipophillic nature and/or due
to an active uptake mechanism (Benitez-King and Anton-Tay 1993; Finocchiaro and Gilkin
1998; Mendez-Pelaez and Reiter 1993). There are three main receptor subtypes which melatonin
can bind to and activate. The MT1 and MT2 receptors are G-protein coupled receptors while the
MT3 receptor belongs to a family of quinine reductases (Witt-Enderby et al. 2003). The MT1
receptor is expressed in the SCN of the hypothalamus as well as cardiac vessels and is involved
in regulating circadian rhythm and constricting blood vessels (Dubocovich et al. 1998; Liu et al.
1997). It has also been found to be expressed in other regions of the brain and peripheral tissues
throughout the body, although its actions here are not fully understood (Witt-Enderby 2003). Not
only can MT1 receptors bind melatonin but they can also bind a wide variety of G-proteins
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eliciting various responses throughout the body (Brydon et al. 1999; Chan et al. 2002). Several
studies have shown that MT1 receptors decrease the activity of PKA due to inhibitory responses
on the cAMP signal transduction cascade as well as decreasing CREB phosphorylation, which
are both involved in the melatonin synthesis pathway (Ganguly et al, 2002; Witt-Enderby et al.
2003). The MT2 receptor, like the MT1 receptor is involved in regulating circadian rhythm and
dilating cardiac vessels as well as being involved in retinal physiology and inflammatory
responses (Dubocovich et al. 1997; Sugden et al. 1999). The MT2 receptor is not as widely
dispersed as the MT1 receptor and is expressed in the SCN, retina, kidneys, ovaries, and cardiac
vessels as well as the sheep placenta (Witt-Enderby et al. 2003; Lemley et al. 2012). The MT3
receptor is unique in that it displays a binding pattern similar to that of the MT2 receptor
(Dubocovich 1995). It was recently affinity-purified from the Syrian hamster kidney and has
been found to share a 95% homology to the quinine-reductase 2 enzyme (Nosjean et al. 2000).
This protein has been found to be expressed in the heart, brain, kidney, liver, lungs, intestines,
spleen, testis, skeletal muscle, and brown adipose tissue of the mouse, dog, monkey, and hamster
(Nosjean et al. 2001).

Melatonin and Pregnancy
Melatonin is unique in that it is one of the few maternal hormones that is able to cross the
placenta unaltered (Torres-Farfan et al. 2008). During prenatal development the fetal pineal
gland is not capable of synthesizing melatonin and relies on maternal production for the supply
of this hormone even though the enzymes responsible for synthesizing indoles are active before
birth (Torres-Farfan et al. 2008; Kennaway et al. 1977). A study conducted by Tamarkin et al.
(1980) examined the post-natal maturation of pineal innervation in hamsters and found that it
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coincides with the development of nocturnal rhythm of melatonin release around the second
week of life. Another study conducted by Klein and Lines (1969) found that in the rat, melatonin
rhythm is dependent on both the innervation of the pineal gland as well as the presence of the
enzymes responsible for the synthesis of melatonin. In sheep, nycthemeral release of melatonin
is not present until the tenth week of postnatal life which may be due to the incomplete
sympathetic innervation of the pineal gland prenatally (Tamarkin et al. 1980; Yellon and Longo
1987). Circulating levels of melatonin in the fetus displays a diurnal rhythm that is directly
related to the maternal release of melatonin; low levels during the day leading to a several fold
increase during the night (Yellon and Longo 1988; Weaver and Reppert 1986). This pattern of
secretion relays information on day length and circadian rhythm to the fetus and plays an
essential role in synchronizing the developing circadian nervous system to the time of day based
on light conditions (Reppert 1985; Reppert et al. 1987). Yellon and Longo (1987) looked at
melatonin rhythm in both the mother and fetus during the last trimester of gestation in sheep.
They found that at day 120 of pregnancy, circulating concentrations of melatonin were present in
all pregnant sheep and was similar to the circulating levels in non-pregnant ewes. They also
reported that fetal concentrations of melatonin were higher during the day (36 pg/ml) compared
to maternal circulating levels (22 pg/ml) and remained this way through day 135 of gestation.
These data indicate that there is a 24-hour pattern of circulating melatonin in the fetus. A similar
study conducted by Yellon and Longo (1988) concluded that the 24-hour pattern of melatonin in
the fetus during the last trimester was directly related to the circadian release of melatonin from
the maternal pineal gland due to undetectable concentrations of melatonin in the fetus after
maternal pinealectomy.
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Melatonin can be detected in essentially every compartment throughout the body
including the human preovulatory follicle, and placenta, and may also be synthesized in the
ovary due to the presence of AANAT and HIOMT, key enzymes involved in the synthesis of
melatonin (Tamura et al. 2009). Several studies have shown that granulosa cell steroidogenesis
and follicular function are altered by melatonin in the hen, hamster, and in humans (Tamura et al.
2009). The melatonin receptors, MT1 and MT2, have been identified in human granulosa and
luteal cells, human and sheep placenta, and also in rat ovaries (Soares et al. 2003; Yie et al. 1995,
Lemley et al. 2012). In the ewe, long term administration of melatonin has been found to have a
stimulatory affect on the hypothalamic-pituitary-ovarian-axis (HPO) by increasing pulsatile
luteinizing hormone releasing hormone (LHRH) and luteinizing hormone (LH) release from both
the hypothalamus and pituitary glands respectively (Aleandri et al. 1996). Woo et al. (2001)
found that melatonin modifies luteal function and also increases mRNA expression of the LH
receptor in human luteal cells. This response could be attributed to antioxidant properties of
melatonin protecting the corpus luteum (CL) from reactive oxygen species (Tamura et al. 2009).
Preventing the regression of the CL would allow production of progesterone during the luteal
phase and early pregnancy (Tamura et al. 2009). Bittman et al. (1985) found that the pulsatile
secretion of LH is mediated by melatonin which controls estradiol negative feedback on the
hypothalamus. Prostaglandin-F2α (PGF2α) is the key hormone responsible for luteolysis and
suppression of progesterone production. Deng et al. (2006) treated a murine macrophage cell line
with supra-physiological concentrations (0.1-1 mM) of melatonin and found that the treatment
inhibited COX-2 gene expression which is the enzyme responsible for the synthesis of PGF2α.
Maintaining the CL until placental takeover in the sheep, by inhibiting the factors which lead to
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its regression, is essential for the continued production of progesterone which is necessary for a
successful pregnancy.

Nutritional Requirements During Gestation
Following conception, the fertilized egg goes through several developmental stages
before becoming a blastocyst around day 7 in the ewe (Senger 2003). Approximately 7-8 days
following fertilization, the blastocyst “hatches” becoming a free floating embryo within the
lumen of the uterus (Senger 2003). At this time, the ovine embryo produces interferon tau which
signals for the maternal recognition of pregnancy and the continued production of progesterone
by the corpus luteum to maintain pregnancy. Before the rapidly growing embryo can attach to
the uterine epithelium, placentation must occur. Ruminants, such as the ewe, have an
epitheliolchorial placenta that is compromised of 60-100 unique structures known as
placentomes (Reynolds et al. 2005). The placentome is the location of nutrient and gas exchange
between the mother and fetus throughout gestation. The maternal portion of these structures,
known as caruncles, are present shortly after birth and their number and location remain constant
throughout the lifespan of the dam (Reynolds et al. 2005). During early gestation the fetal
portion of the placentome, the cotyledon, develops from the chorion and attaches to the caruncle
approximately 15-18 days after ovulation (Senger 2003). Placental growth in terms of mass
occurs during the first two thirds of gestation and placentomes reach their maximum size and
weight around day 90 of gestation, while 90% of fetal growth occurs during the last third of
pregnancy (Sammin et al. 2009; Redmer et al. 2004).
Adequate maternal nutrition during gestation is essential for the proper growth and
survival of the developing conceptus. The placenta is responsible for transferring nutrients to the
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fetus which can be altered due to the size and nutrient transfer capacity of the placenta (Redmer
et al. 2004). The nutrient exchange system between the dam and the fetus is dependent on both
the uterine and umbilical blood flow which is in turn dependent on the adequate vascularization
of the placenta (Redmer et al. 2004). Without proper nutrient transfer, which is largely dependent
on blood flow, fetal growth and proper development can be significantly reduced. Studies using a
growth restricted model (ewes restricted 40% compared to controls) have constantly shown that
when pregnant ewe lambs are nutrient restricted during various periods of gestation, lamb birth
weight is reduced (Meyer et al. 2010; Swanson et al. 2008), umbilical artery blood flow during
mid-gestation is reduced (Lemley et al. 2012), and umbilical vascular resistance is increased
(Vonnahme 2012). On the other hand, studies conducted by Wallace et al. (1996, 1997) have
shown that over nourishing adolescent ewes throughout gestation led to a decrease in placental
mass and a significant reduction in lamb birth weight at parturition. Over nourishment during
gestation in the adolescent ewe favors maternal growth instead of partitioning nutrients to
support the growth of the gravid uterus leading to inadequate growth of the fetus (Wallace et al.
2009). A similar study conducted by Wallace et al. (2003) found that overfeeding mature ewes
throughout gestation had no effect on fetal growth. In summary, these data indicate that proper
nutrient intake during gestation is essential for the proper growth and development of the fetus.
Intrauterine growth restriction (IUGR) is not limited to feed intake but can also be caused by
environmental conditions such as elevated temperatures leading to heat stress (Vonnahme 2012).
A study conducted by Regnault et al. (2003) induced IUGR by placing pregnant ewes in
hyperthermic conditions beginning on day 39 of gestation and ending near term. They found that
ewes exposed to hyperthermic conditions throughout gestation had placentas which were
approximately 50% smaller than those from control ewes. A decrease in placental size is not seen
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mid to late term in nutrient restricted ewes during gestation, on the contrary, placental size in
nutrient restricted ewes increases and may be due to the need to scavenge more nutrients from
the blood (Vonnahme 2012).
Nutrients are delivered to various tissues throughout the maternal body based on the
metabolic rate of those tissues (Hammond 1944; Barcroft 1946). When nutrients are limited,
tissues with a lower metabolic rate have less priority to receive nutrients than do tissues with
higher metabolic activities (Redmer et al. 2004). Tissues with high metabolic activity have
greater nutrient delivery due to increased blood flow to those tissues, thus blood flow is the
limiting factor of nutrient delivery to specific tissues (Redmer et al. 2004). During gestation the
gravid uterus receives a large portion of cardiac output to support the growing conceptus,
however, during compromised pregnancies blood flow to the gravid uterus is reduced in order to
support the needs of the dam (Barker et al. 1997; Redmer et al. 2004; Reynolds et al. 2005).
When nutrient intake is restricted, the rate of cell division is significantly reduced which is either
due to the effect of undernutrition or the altered concentration of growth factors such as insulin
like growth factors and/or growth hormone (Barker et al. 1997). The decrease in specific factors
required for the proper growth and development may lead to the improper growth of the
developing fetus.
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Introduction
Melatonin is a neurohormone produced from the amino acid tryptophan and secreted
from the pineal gland on a diurnal rhythm depending on environmental lighting conditions.
Melatonin has been found to regulate seasonal reproduction in a variety of animals including the
ewe (Monroe et al. 1998; Yellon and Longo 1987). Additionally, melatonin is unique in that it is
one of the few maternal hormones that is able to cross the placenta unaltered (Torres-Farfan et al.
2008). Previous studies have shown that melatonin supplementation has been associated with
decreasing uterine contractility in the rat, stimulating the secretion of progesterone (Forcada et
al. 2006), increasing the release of gonadotropins from the pituitary in the ewe (Aleandri et al.
2006), and removal of the pineal gland in pregnant rats has been linked to an elevated incidence
of spontaneous abortions (Sandyk et al. 1992).
Adequate maternal nutrition during gestation is essential for the proper growth and
survival of the developing conceptus. During gestation in mammals, the placenta is the organ
which is responsible for the transfer of nutrients, oxygen, and immunological factors such as
cytokines and lymphocytes from the mother to the fetus. Studies have shown that when pregnant
ewe lambs are nutrient restricted during various periods of gestation, lamb birth weight is
reduced (Meyer et al. 2010; Swanson et al. 2008), umbilical artery blood flow during mid
gestation is reduced (Lemley et al. 2012), and umbilical vascular resistance is increased
(Vonnahme 2012). These data indicate that proper nutrient intake during gestation is essential for
the proper growth and development of the fetus.
Lemley et al. (2012, 2013) found that supplementing ewes with melatonin either through
the feed or direct infusion into the mesometrial region of the gravid uterus during mid gestation
decreased caruncle weight (2013), increased fetal abdominal girth (2012), and increased
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umbilical blood flow (2013). These results led us to hypothesize that supplementation with
melatonin during mid gestation would offset the negative effects of nutrient restriction during
mid gestation and increase placental cell proliferation. The hypothesis was tested through two
separate studies. First, we wanted to determine the effects of chronic in vivo infusions of vehicle,
melatonin or melatonin antagonist on placental cell proliferation during mid-gestation. Secondly,
we wanted to determine if supplementing melatonin directly into the feed would increase
placental cell proliferation in ewes that were nutrient restricted during mid gestation.

Materials and Methods
All protocols involving animals were approved by the North Dakota State University
Intuitional Animal Care and Use Committee protocol #A11061 (infusion study) and protocol
#A10071 (dietary study).

Animal management for Infusion Study
The animal management, breeding, and experimental design were previously published
(Lemley et al., 2013). Initially, 24 primiparous ewes were placed on pasture with ad libitum
access to hay and water with one ram of proven fertility fitted with a crayon marking harness.
Mating was recorded every 12 hours. At day 28 after breeding, ewes were transported to the
Animal Nutrition and Physiology Center (ANPC; Fargo, ND) which is a temperature controlled
facility (14˚C) with a 12:12 light: dark cycle with lights on at 07:00 hours and off at 19:00 hours
for the remainder of the study. The study was conducted in August of 2011 and ewes were fed to
meet early gestational nutrient requirements beginning on day 28 of gestation. Ewes carrying
singleton pregnancies were assigned to treatments and housed in individual pens (0.91 x 1.2 m)
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at ANPC for the remainder of the experiment. On day 35 of gestation ewes were acclimated to a
common alfalfa hay diet (2% of body weight), provided trace mineralized salt blocks (American
Stockman, Overland Park, KS), and ad libitum access to water.

Surgeries for Infusion Study
Melatonin was purchased from Spectrum Chemical Mfg. Corp. (Gardena, CA) and
luzindole was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). One day prior
to surgery (day 61 of gestation) Alzet mini-osmotic pumps (model 2ML4; Durect Corporation,
Cupertino, CA) were prepared using aseptic techniques. The 2ML4 model has a mean pumping
rate of 2.80 μL/hr (standard deviation of 0.14 μL/hr), a mean fill volume of 2100 μL, and a
pumping duration of 28 days (without catheter attachments). Melatonin and luzindole were
prepared at a concentration of 1 mg/mL in vehicle and then sterile filtered. In addition, vehicle
alone (45% DMSO in water) was sterile filtered for control ewes. Melatonin, luzindole, or
vehicle were loaded into mini-osmotic pumps and then attached to a 20 cm PE-60 polyethylene
catheter preloaded with the respective infusion treatment. The mini-osmotic pump and catheter
attachment were completely submerged in sterile filtered saline and kept at 37˚C overnight (one
day prior to surgery).
On day 62 of gestation, ewes were weighed and anesthetized with sodium pentobarbital
at 3 mg/kg sodium pentobarbital per 20 kg of body weight. Anesthesia was maintained via a
jugular catheter. The abdomen was sheared and cleaned with betadine scrub. Through a mid-line
abdominal incision the gravid uterine horn was exposed. During surgery the uterus was covered
with warm surgical towels, and liberal amounts of sterile saline (37˚C) were applied to the uterus
every 5 minutes. Pumps and catheters were sutured under the perimetrium and catheters were
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advanced to the gravid uterine vascular network (arterial and venous) of the mesometrial region.
Post-surgical care consisted of twice daily i.m. injections of flunixin meglumine (50 mg/mL;
Prevail; Meridian, ID) and once daily i.m. injections of Penicillin G Procain (300,000 U/mL;
Durvet; Blue Springs, MO) for the first 2 days post-surgery, following manufacturer
recommendations. In addition, ewes were provided 50% of their rations post-surgery and feed
was increased in a stepwise manner during this post-operative phase. Fifteen ewes were selected
for this surgical procedure and all fetuses were viable during the 4 week infusion period;
however, one ewe was removed because of a twin pregnancy.

Tissue Collection for Infusion Study
On day 90 of gestation (following the 4 week chronic uterine infusion) ewes were
euthanized via captive bolt followed by exsanguination. The uterus was removed at the cervix
and the fetus was dissected from the gravid uterine horn. Fetal membranes were removed and
several placentomes were dissected from the uterine wall, weighed, and flash frozen for later
analysis. Caruncular and cotyledonary tissues were separated, weighed, flash frozen, and stored
at -80°C for further analysis.

Animals and Treatments for Dietary Study
The animal management, breeding, and experimental design were previously published
(Lemley et al. 2012). Nulliparous Western white face ewe lambs (n=64) and 2 rams fitted with
crayon marking harnesses were put on pasture with ad libitum access to hay and water. Mating
was recorded daily at twelve hour intervals. On d 28 of gestation, dams were transported to the
Animal Nutrition and Physiology Center (ANPC; Fargo; ND) which is a ventilated, temperature
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controlled facility (14°C) with 12:12 h light-dark cycle with lights on at 07:00 and off at 19:00.
The study was conducted in September of 2010 and ewes were fed to meet their early gestational
nutrition requirements beginning on d 28 of gestation. At ANPC, pregnancy was determined
during days 28 through 35 using a B mode ultrasound (model SSD-3500; Aloka America,
Wallingford, CT) fitted with a 7.5 MHz, linear transrectal probe, adapted from Schrick and
Inskeep (1993; Lemley et al. 2012). Lutalyse was administered to ewes carrying multiple
conceptuses and reintroduced to the rams 2 wk later. Ewes carrying singletons were individually
housed in 0.91 x 1.2m pens at ANPC for the duration of the study.
Previous work conducted at NDSU on mid- to late-gestational maternal under nutrition
has shown to be an effective model to observe the effects of under nutrition during this stage of
pregnancy. This IUGR model has consistently resulted in decreased fetal weight, decreased birth
weight, no difference in placental weight, and decreased postnatal growth rates (Meyer et al.,
2010; Lemley et al., 2012).

Nutritional Supplementation for Dietary Study
On d 50 of gestation, ewes were assigned to one of four treatment groups consisting of 5
mg of melatonin (MEL; Spectrum Chemical Mfg., Gardena, CA) or no melatonin (CON) and
supplied 100% (adequate diet; ADQ) or 60% (restricted; RES) of NRC recommendations (1985)
for the remainder of the study. The four resulting treatment groups consisted of CON-ADQ
(n=7), MEL-ADQ (n=8), CON-RES (n=8), MEL-RES (n=8). Nutrient recommendations were
set based on the mid- to late- gestational requirements for a 60 kg body weight pregnant ewe
lamb. All ewes were fed and/or supplemented five hours before the start of the dark cycle at
1400 with melatonin enriched pellets. A melatonin solution was made by dissolving powered
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melatonin in 95% ethanol at a concentration of 5 mg/ml. A day prior to feeding, 1 ml of the
melatonin solution was applied to control pellets (100g) and placed in a plastic bag to allow the
ethanol to evaporate overnight at room temperature with no exposure to light (Lemley 2012). At
1400, the melatonin supplemented pellets (100g) were fed to the MEL groups and were
consumed within ~5 minutes. After the consumption of the melatonin treated pellets, the
remainder of the control pellet was divided between all melatonin treated animals.

Tissue Collection for Dietary Study
On day 130 of gestation, ewes were weighed and anesthetized with sodium pentobarbital
at 3 mg/kg of body at 08:00. A catheter was inserted into the jugular vein and used to maintain
anesthesia via intermittent infusion with sodium pentobarbital. The following surgical
procedures were non-survival; however aseptic techniques were used to preserve tissue samples
for later analysis. The abdomen was sheared and cleaned with Betadine and the uterus was
exposed via a midventral laparotomy, covered with warm surgical towels and liberal amounts of
saline (37°C) were applied to the uterus every 5 minutes. Intraoperative uterine and umbilical
blood flows were determined using duplex B-mode and D-mode program of the color Doppler
ultrasound instrument (Lemley et al., 2012). Prior to ewe euthanasia the gravid uterine horn was
dissected and the fetus was removed under general anesthesia before the uterus was removed at
the cervix. Fetal membranes were removed and several placentomes were dissected from the
uterine wall, weighed, and flash frozen for later analysis. Caruncular and cotyledonary tissues
were separated, weighed, flash frozen, and stored at -80°C for further analysis.

Measurement of Placentome Cellular Proliferation
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Placentomes excised from pregnant ewes on days 90 (infusion study; Experiment 1) and
130 (feeding study; Experiment 2) of gestation were analyzed using an immunofluorescence
protocol developed at NDSU specific for cell proliferation. Fresh placentomes were fixed in a
10% solution of neutral buffered formalin containing 4% formaldehyde for < 24 hours and
transferred to a 70% ethanol solution. After fixation, the placentomes were embedded in paraffin
and 5 µm tissue sections were made and mounted on glass slides to prepare for staining. The
prepared tissue samples from all ewes were incubated with a KI-67 mouse monoclonal antibody
(VP-k452 Vector Laboratories) at 1:350 (6 µL/2.1 mL of blocking buffer). To label the primary
antibody, a goat anti-mouse IgG secondary antibody conjugated to Alexa-647 fluorophore (A21235, Life Technologies) was applied to the slides for a 1 hour incubation period. In order to
differentiate between the maternal and fetal sides of the placentome, rhodamine labeled lectin
(RL-1102, Vector Laboratories) was applied to the slides following the secondary antibody
incubation. Before applying the cover slips, a drop of Prolong Gold anti-fade reagent with DAPI
(P36931, Life Technologies) was added to each slide as a nuclear counter stain. Cellular
proliferation was quantified using Image-Pro Plus (Media-Cybernetics Inc.).

Image Analysis
Photomicrographs were taken at 20x magnification in a low light environment using a
Zeiss Axio Imager 2 microscope (Zeiss, Oberkochen, Germany). Because KI-67, rhodamine
lectin and DAPI fluoresce at different wave lengths (625nm, 555nm, and 365nm respectively), a
picture was taken at each specific wave length. The three pictures were then overlaid to get a
representative image of the sample. This was repeated at four other random sections of the slide
for each sample. The resulting images were analyzed using Image-Pro Plus software (Media-
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Cybernetics Inc). For each image, the fetal and maternal portions were distinguished and a macro
was developed to quantify the total area of maternal or fetal tissue as well as the area of
proliferating and non-proliferating cells. By obtaining the average area of a proliferating and
non-proliferating cell, the quantity of each could be determined for each treatment group.

Cellularity Estimates (DNA, RNA, and Protein)
Individually frozen caruncular and cotyledonary tissues were ground into a fine powder
using a mortar and pestle while submerged in liquid nitrogen and transferred to a chilled tube to
allow the excess liquid nitrogen to evaporate. AllPrep DNA/RNA/Protein Mini kit (Qiagen,
Hilden, Germany) was used to quantify the amount of DNA, RNA, and protein present in both
cotyledonary and caruncular tissues from both the infusion and feeding studies. Supplied buffer
(buffer RLT) was then added and the sample was homogenized using a Tissuemiser (Fisher
Scientific, Waltham, MA). The lysate was centrifuged at full speed (18,000 RCF) for three
minutes before being transferred to a DNA spin column. DNA and RNA were extracted and
washed according to Qiagen’s protocol and were eluted to a final volume of 50 µL of RNase free
water (RNA), or 100 µL of Buffer EB (DNA) before being quantified using NanoDrop
spectrophotometer (ND-1000, Thermo Scientific, Waltham, MA).
Tissue homogenates suspended in buffer (buffer RLT, Qiagen) were used to assess total
protein. The prepared tissue homogenates were quantified with Coomassie Brilliant blue G
(Bradford, 1976) using bovine serum albumin (Thermo Scientific, Waltham, MA) as the
standard. The prepared samples were measured at 595nm using a spectrophotometer (Spectra
Max Plus 384, Molecular Devices, Sunnyvale, CA). The concentration of DNA was used as an
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index of cell number with protein:DNA ratio a measure of cell size, and RNA:DNA ratio used as
an index of transcriptional activity (Reed 2007).

Statistics
Data for the melatonin infusion were analyzed using the MIXED procedure of SAS (SAS
Software version 9.2, SAS Institute Inc., Cary, NC). Fetal sex was included in the model, and it
was removed if P ≥ 0.25. The model compared means across all three treatments; control (con),
melatonin (mel), or luzindole (luz). Data were considered significant if the P < 0.10.
Data for the melatonin feeding study were analyzed as a completely randomized 2x2
factorial design using the MIXED procedure of SAS (SAS Software version 9.2, SAS Institute
Inc., Cary, NC). Fetal sex and breeding date were included in the model to help control for
variation in the number of male vs. female fetuses or the date of breeding. If fetal sex and
breeding date had a P ≥ 0.25, they were removed from the model statement. The model
contained the effects for nutritional plane (adequate and restricted), melatonin supplementation
(control versus melatonin), and the interaction between nutritional plane and melatonin
supplementation. In the absence of interactions, main effects were considered significant when P
˂ 0.05.

Results
Study 1 (Infusion Study)
Gross weights and blood flow
Maternal body weight, placental size, fetal size, and umbilical blood flow at day 90 of
gestation are illustrated in Table 1. These data were adapted from Lemley et al. (2013). Ewe final
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body weight, gravid uterine weight, and empty uterine weight at day 90 of gestation were not
different (P > 0.30) across all treatment groups. Placentome weight and cotyledon weight were
not different (P > 0.08) across all treatment groups at day 90 of gestation; however, caruncle
weight was decreased (P < 0.05) in both LUZ and MEL infused dams versus CON infused. Fetal
weight, crown rump length, and ponderal index at day 90 of gestation were not different (P >
0.10) across all treatments. In contrast fetal abdominal girth was increased (P < 0.05) in
melatonin versus luzindole infused dams with vehicle control infused dams being intermediate
(Table 1).

Cellularity estimates
Placental cellularity estimates are illustrated in Table 2. In caruncular tissue, treatment
did not affect (P ≥ 0.15) the concentration of DNA, RNA or protein. There was no effect (P ≥
0.21) of treatment on the ratio of DNA:RNA, and the ratio of protein:DNA. In cotyledonary
tissue, there was no effect (P ≥ 0.17) of melatonin, luzindole or vehicle infusion treatment on
DNA, RNA, or protein concentrations. The DNA:RNA ratio as well as the protein:DNA ratio
was also not affected by treatment (P ≥ 0.60).

Placentome cellular proliferation
Placentome cellular proliferation is illustrated in Table 2. Treatment of ewes with 1
mg/mL of melatonin, luzindole, or vehicle delivered at a rate of 2.80 µL/hr for 28 days did not
affect (P ≥ 0.30) the percentage of KI-67 positive cells in either caruncular or cotyledonary
tissue. There was also no effect (P ≥ 0.39) of fetal sex on the percentage of KI-67 positive cells
in either caruncular or cotyledonary tissue (data not shown).
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Table 1. Ewe body weight, placenta size, fetal size, and uteroplacental blood flow at day 90 of gestation from ewes
chronically infused with luzindole (LUZ), vehicle control (CON), or melatonin (MEL) beginning on day 62 of
gestation.

‡

Dependent variable
Ewe weight, kg
Gravid uterine weight, kg
Empty uterine weight, g
Placenta
Placentome weight, g
Caruncle weight, g
Cotyledon weight, g
Fetal weight, g
Crown rump length (cm)
Ponderal index (kg/m3)
Abdominal girth (cm)
Umbilical artery, ml/min

LUZ
69.2
2.6
359
590
102b
432
572
26
32
16.7b
130b

CON
64.2
2.4
364
551
159a
363
567
27
29
17.5ab
141b

MEL
67.8
2.6
388

SE
5.9
0.2
16

490
97b
329
612
27
29
18.2a
200a

43
13
35
43
1
1
0.4
17

P-value
Trt
0.82
0.74
0.36
0.21
0.01
0.09
0.67
0.33
0.15
0.01
0.02

a,b
‡

Least square means with different letter superscripts depict differences P < 0.05.
Data adapted from Lemley et al. (2013).
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Table 2. Placenta measures of DNA, RNA, protein and cellular proliferation at day 90 of gestation from ewes
chronically infused with luzindole (LUZ), vehicle control (CON), or melatonin (MEL) beginning on day 62 of
gestation.
P-value
Dependent variable

LUZ

CON

MEL

SE

Trt

Caruncle
DNA, mg/g

4.3

3.7

4.6

0.6

0.48

RNA, mg/g

5.4

5.5

5.2

0.9

0.97

Protein, mg/g

124

128

131

3

0.15

RNA:DNA

1.5

1.8

1.2

0.4

0.31

Protein:DNA

32

47

33

8

0.21

Proliferating cells, %

1.2

1.9

1.5

0.2

0.39

DNA, mg/g

4.1

3.0

4.3

1.3

0.66

RNA, mg/g

8.2

5.1

7.0

1.4

0.17

Protein, mg/g

143

139

144

4

0.44

RNA:DNA

2.4

1.7

1.8

0.7

0.60

Protein:DNA

42

48

42

11

0.84

Proliferating cells, %

8.3

8.1

6.7

1.7

0.47

Cotyledon

28

12

Percent KI-67 Positive Cells

10

8

Con
6

Luz
Mel

4

2

0

Fetal

Maternal

Figure 1. Cellular proliferation based on percent KI-67 positive cells at day 90 of gestation from ewes chronically
infused with luzindole (LUZ), vehicle control (CON), or melatonin (MEL) beginning on day 62 of gestation.
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Study 2 (Dietary Study)
Gross weights
Maternal body condition, placental size, fetal size, and uteroplacental blood flow at day
130 of gestation are illustrated in Table 3. These data were adapted from Lemley et al. (2012).
Ewe final body weight and empty uterus weight at day 130 of gestation were decreased in RES
versus ADQ fed ewes. No main effects or interactions were observed for placentome weight or
placentome number (P > 0.10). Fetal weight was decreased (P < 0.01) in RES versus ADQ fed
ewes. At day 130 of gestation umbilical blood flow was increased (P < 0.05) by approximately
20% in MEL versus CON ewes, with no effect (P > 0.30) of nutritional plane on umbilical artery
blood flow. In contrast, uterine artery blood flow was decreased (P < 0.05) by approximately
20% in RES versus ADQ fed ewes, with no effect (P > 0.25) of melatonin supplementation on
uterine artery blood flow.

Cellularity estimates
Placental cellularity estimates are illustrated in Table 4. There was no effect (P ≥ 0.21) of
nutritional plane or melatonin treatment on DNA or protein concentrations in caruncular tissue.
However, there was a significant (P = 0.02) melatonin treatment x nutritional plane interaction
for maternal RNA concentrations in caruncular tissue. Ewes treated with melatonin under a
restricted diet had an increase in RNA concentration compared to adequately fed ewes treated
with melatonin. Although there were no melatonin treatment x nutritional plane interactions on
the ratio of RNA:DNA or the ratio of protein:DNA in caruncular tissue. In cotyledonary tissue,
neither melatonin supplementation nor nutritional plane affected (P ≥ 0.20) DNA, RNA, or
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Table 3. Ewe body weight, placenta size, fetal size, and uteroplacental blood flow at day 130 of gestation from ewes
supplemented with 5 mg of melatonin (MEL) or no melatonin (CON) and provided 100% (ADQ; adequate diet) or 60%
(RES; restricted diet) of nutrient recommendations beginning on day 50 of gestation.
P-values†
Dependent variable‡
Ewe weight, kg
Empty uterus weight, g
Placentome weight, g
Fetal weight, g
Crown rump length, cm
Ponderal index3, kg/m3
Abdominal girth, cm
Uterine artery, ml/min
Umbilical artery, ml/min

CON
ADQ
53
653
478
3405
53.6
22.2b
32.5b
1261
650

CON
RES
41
557
436
3173
51.7
22.9b
32.1b
1023
643

MEL
ADQ
51
674
488
3691a
52.5
25.9a
34.1a
1520
805

MEL
RES
41
530
448
3066
51.7
22.4b
31.7b
1094
710

SE

Trt

1
24
30
110
0.9
1.1
0.4
165
67

0.56
0.88
0.70
0.40
0.52
0.11
0.09
0.30
0.04

Nut

Trt*Nut

<0.01
<0.01
0.17
<0.01
0.15
0.19
<0.01
0.04
0.37

0.64
0.32
0.97
0.07
0.52
0.04
<0.01
0.55
0.42

a,b

Least square means with different letter superscripts depict differences P ≤ 0.05.
Main effect of melatonin supplementation (Trt), main effect of nutritional plane (Nut), or the interaction between
melatonin supplementation × nutritional plane (Trt*Nut). Least square means and SEM for main effects are reported in
the text.
‡
Data adapted from Lemley et al. (2012).
Ponderal index calculated as fetal weight (kg)/crown rump length (m) 3.
†

31

Table 4. Placenta measures of DNA, RNA, protein and cellular proliferation at day 130 of gestation from ewes
supplemented with 5 mg of melatonin (MEL) or no melatonin (CON) and provided 100% (ADQ; adequate diet) or 60%
(RES; restricted diet) of nutrient recommendations beginning on day 50 of gestation.
P-values†
Dependent variable
Caruncle
DNA, mg/g
RNA, mg/g
Protein, mg/g
RNA:DNA
Protein:DNA
Proliferating cells, %
Cotyledon
DNA, mg/g
RNA, mg/g
Protein, mg/g
RNA:DNA
Protein:DNA
Proliferating cells, %

CON
ADQ

CON
RES

MEL
ADQ

MEL
RES

SE

Trt

Nut

Trt*Nut

2.2
2.8ab
137
1.4
85
0.69

2.3
1.8b
134
1.1
73
0.70

1.8
2.0b
133
1.2
78
0.76

2.8
4.5a
129
1.8
63
0.92

0.4
0.8
3
0.5
13
0.04

0.83
0.20
0.14
0.69
0.48
0.33

0.18
0.31
0.20
0.74
0.28
0.58

0.20
0.02
0.95
0.33
0.91
0.59

5.2
6.3
124
1.7
36
5.6

4.6
7.6
122
1.9
33
5.3

4.9
7.1
124
1.7
31
6.6

5.2
6.7
122
1.4
29
6.7

0.9
0.7
3
0.3
8
0.7

0.88
0.92
0.91
0.35
0.54
0.08

0.83
0.51
0.47
0.98
0.76
0.73

0.50
0.20
0.85
0.25
0.92
0.58

a,b

Least square means with different letter superscripts depict differences P ≤ 0.05.
Main effect of melatonin supplementation (Trt), main effect of nutritional plane (Nut), or the interaction between
melatonin supplementation × nutritional plane (Trt*Nut). Least square means and SEM for main effects are reported in
the text.
†
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protein concentrations. There was no effect (P ≥ 0.25) of nutritional plane or melatonin treatment
on the RNA:DNA ratio or the ratio of protein:DNA in cotyledonary tissue.

Placentome cellular proliferation
Placentome cellular proliferation is illustrated in Table 4. There were no melatonin
treatment x nutritional interactions (P ≥ 0.58) or main effects of nutritional plane (P ≥ 0.58) on
placentome cellular proliferation of the caruncle or cotyledon. There was a tendency (P = 0.08)
for melatonin supplemented ewes to have an increased percentage of KI-67 positive cells in
cotyledon tissue, but this effect was not present (P > 0.33) in caruncle tissue.
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Figure 2. Cellular proliferation based on percent KI-67 positive cells at day 130 of gestation from ewes supplemented
with 5 mg of melatonin (MEL) or no melatonin (CON) and provided 100% (ADQ; adequate diet) or 60% (RES;
restricted diet) of nutrient recommendations beginning on day 50 of gestation.
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Discussion
The present study indicates that chronic infusion with melatonin does not alter placental
cellular proliferation when infused during mid-gestation. This observation does not suggest that
melatonin does not play a role in increasing cellular proliferation during other stages of
gestation. The majority of placental development occurs during the first two thirds of gestation
(Redmer et al. 2004). Melatonin treatment may have varying levels of affect during early
gestation when placental growth is just starting, although there have been no reports on the effect
of melatonin infusion on cellular proliferation at this time point of pregnancy. Lemley et al.
(2013) reported placentome weight and cotyledon weight were not different across all treatment
groups at day 90 of gestation however, caruncle weight at day 90 of gestation was decreased in
ewes infused with either luzindole or melatonin compared to controls. This indicates that
placental growth may be altered by melatonin infusion during mid gestation. Sammin et al.
(2009) found that placentomes reach their maximum size and mass by day 90 of gestation which
explains why there was no difference in placentome weight between the three treatment groups
at day 90 of gestation. However, the decrease in caruncle weight could be attributed to an
increase in cellular turnover, although the exact mechanism by which this occurs remains
unclear. Lemley et al. (2013) found that chronic infusion with melatonin, luzindole or vehicle
for a 28 day period during mid-gestation did not alter ewe final body weight, gravid uterine
weight, or empty uterine weight. Fetal growth parameters including fetal weight, crown rump
length, and ponderal index were not different between the three treatment groups at day 90 of
pregnancy (Lemley et al. 2013). However, fetal abdominal girth was increased in melatonin
versus luzindole infused dams with vehicle infused dams being intermediate (Lemley et al.
2013). In our study, the same treatment did not alter the concentration of DNA, RNA or protein
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in any of the treatment groups as well as not altering the ratio of DNA:RNA or the ratio of
protein:DNA in fetal or maternal tissues.
Dietary treatment with 5 mg of melatonin per day for 80 days had a tendency to increase
the percentage of proliferating cells in cotyledonary tissue although there was no effect in
caruncular tissue. The precise mechanisms by which melatonin increases placentome cellular
proliferation in cotyledonary tissue remains to be determined and needs to be further
investigated. During the last third of gestation the rate of fetal development is greatly increased
(Redmer et al. 2004). Additionally, placental and fetal nutrient requirements are highest during
late pregnancy and in order for these nutrients to be delivered at a rate to keep pace with fetal
growth, blood flow to the fetus must increase (Wallace et al. 2004). During late gestation in
nutrient restricted pregnancies, uterine and umbilical blood flows are impaired (Reynolds et al.
2005). In the current work, Lemley et al. (2012) found that maternal melatonin supplementation
during mid to late gestation increased umbilical blood flow by approximately 20% compared to
control ewes. However, melatonin treatment did not alter uterine artery blood flow compared to
controls (Lemley et al. 2012). There was also no affect of nutritional plane on placental cellular
proliferation in either fetal or maternal tissues. Lemley et al. (2012) found that there was no
change in placentome weight or number at day 130 of gestation due to placental development
being complete at this period of pregnancy. RNA concentration was increased in the caruncular
tissue of nutrient restricted ewes treated with melatonin although this was not seen in
cotyledonary tissue. The increase in total RNA within the maternal portion of the placentome
may be linked to an increase in gene expression and subsequently protein synthesis in caruncular
tissue. Reactive oxygen species (ROS) especially O2●- react with nitric oxide (NO) to form
peroxynitrite (ONOO-) which is a known oxidant and nitrating agent (Richter et al. 2009). This
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specific ROS has been shown to cause oxidative cellular damage and reduced blood flow due to
the increase in sequestration of NO which is important in maintaining blood flow in placental
and umbilical circulations (Schultz et al. 2004). A study conducted by Richter et al. (2009) found
that nutrient restricted rats treated with melatonin had a significant increase in expression of the
antioxidant enzymes Mn-SOD and catalase. This increase in antioxidant activity may decrease
free radical production and ROS allowing for an increase in placental perfusion and the delivery
of nutrients to the fetus in nutrient restricted pregnancies. However, there have been no studies
looking at the affect of melatonin on the expression of antioxidant enzymes in the placenta of a
nutrient restricted ewe. In our current study, the increased RNA concentration in caruncular
tissue as well as the increase in umbilical blood flow reported by Lemley et al (2012) may be due
to the antioxidant properties of melatonin. However, further research needs to be conducted
regarding the role of melatonin on increasing the expression of antioxidant enzymes in an ovine
model of IUGR.
To our knowledge there have been no reported studies on both the dietary treatment and
infusion of melatonin and its effects on cellular proliferation during mid-gestation in an ovine
model. However, there have been numerous studies on the effects of nutrient restriction on fetal
growth and placental development during different times of pregnancy. Placental growth in
terms of mass occurs during the first two thirds of gestation and maximal proliferative placental
growth occurs between days 50 and 60 (Redmer et al. 2004; Heasman et al. 1998). The placenta
is responsible for transporting nutrients to the fetus throughout gestation and without proper
nutrient transfer, which is largely dependent on blood flow; fetal growth and development can be
significantly reduced. Studies have shown that when ewes are nutrient restricted for periods of
time throughout gestation, placental growth is reduced (McCrabb et al. 1991), birth weight is
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reduced (Meyer et al. 2010), amino acid concentration in both fetal and maternal blood plasma is
reduced (Kwon et al. 2004), and placental angiogenesis is altered (Reynolds et al. 2005).
Additionally, Clark et al. (1998) found that feeding ewes with half of the energy required to
maintain pregnancy from day 30-80 of gestation, reduced mean placentome weight and total
cotyledonary weight compared to animals fed to meet their nutrient requirements. In the present
study, Lemley et al. (2012) found that nutrient restricted ewes had a decreased final body weight
and empty uterine weight compared to adequately fed ewes with no main affect of melatonin
supplementation. Moreover, fetal weight was reduced in nutrient restricted ewes compared with
adequately fed ewes with no melatonin by nutritional plane interaction (Lemley et al. 2012).
In conclusion, supplementing melatonin during mid-gestation either through the diet or
infusion may help reduce the effects of IUGR, although this needs further investigation to better
understand the mechanisms involved. Our results show that melatonin supplementation has a
tendency to increase cotyledonary cell proliferation as well as increasing caruncular RNA
expression and fetal umbilical blood flow. Methods that increase umbilical blood flow, cellular
proliferation, and protein synthesis (as a result of increased RNA expression), may help rescue
IUGR pregnancies.
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